Activated phosphoinositide 3-kinase delta syndrome (APDS)

Active Ingredient: Leniolisib

Indication for Leniolisib

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Leniolisib is indicated for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS) in adults and adolescents 12 years of age and older and weighing 45 kg or more.

For this indication, competent medicine agencies globally authorize below treatments:

70 mg once every 12 h

For:

Dosage regimens

In the case that patient weight is ≥ 45 kg :

Oral, 70 milligrams leniolisib, once every 12 hours.

Detailed description

The recommended dose is 70 mg leniolisib twice daily approximately 12 hours apart. Leniolisib is indicated in adults and adolescents 12 years of age and older and weighing 45 kg or more.

Treatment should be continued as long as a benefit is observed or until unacceptable toxicity occurs.

Missed dose

If a dose is missed by more than 6 hours, the patient should not take the missed dose but resume dosing at the next scheduled time.

If vomiting occurs within 1 hour after taking leniolisib, the patient should take another leniolisib tablet as soon as possible. If vomiting occurs more than 1 hour after dosing, the patient should not take an additional dose.

Elderly

There are no data on patients aged 65 years and older. No dosing modifications are recommended for elderly patients.

Dosage considerations

Gastric acid reducing agents

For patients using locally acting antacids chronically, the antacid should be taken either 2 hours before or 2 hours after leniolisib administration.

Active ingredient

Leniolisib

Leniolisib inhibits PI3K-delta by blocking the active binding site of PI3K-delta. In cell-free isolated enzyme assays, leniolisib was selective for PI3K-delta over PI3K-alpha (28-fold), PI3K-beta (43-fold), and PI3K-gamma (257-fold), as well as the broader kinome. In cell-based assays, leniolisib reduced pAkt pathway activity and inhibited proliferation and activation of B and T cell subsets.

Read more about Leniolisib

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.